Forthcoming Paper
“Firm listing status, firm size, and the financing of investment” by Mathias Lé and Frederic Vinas
RCFS News
Paper Spotlight: Agency Conflicts and Investment: Evidence from a Structural Estimation
Agency problems between managers and shareholders affect both investment and capital structure decisions at firms. In “Agency Conflicts and Investment: Evidence from a Structural Estimation,” Redouane Elkamhi, Daniel Kim, Chanik Jo, and Marco Salerno develop and structurally estimate a dynamic model to understand the real and financial implications of such agency problems. The manager in the model is pulled into two different directions. On… Read More »Paper Spotlight: Agency Conflicts and Investment: Evidence from a Structural Estimation
Forthcoming Paper
“Competing for Deal Flow in Local Mortgage Markets” by Darren James Aiello, Mark Garmaise, and Gabriel Natividad
Forthcoming Paper
“Deposit Insurance Premiums and Bank Risk” by Edward T. Kim and Marcelo Rezende
Paper Spotlight: Do Security Analysts Discipline Credit Rating Agencies?
Credit ratings agencies are important players in financial markets and they could contribute to efficient resource allocations through information generation. Often, though, expectations of this positive impact are not met in reality because of well-documented biases that credit rating agencies suffer from. Such issues can be due to revolving doors, home biases, and political beliefs of credit analysts. These biases can ultimately have a… Read More »Paper Spotlight: Do Security Analysts Discipline Credit Rating Agencies?
Forthcoming Papers
“Price Uncertainty and Debt Covenants: Evidence from US Oil Producer” by Sandrine Docgne and Diogo Duarte “Regulatory Spillovers in Local Mortgage Markets” by Ivan Lim, Duc Duy Nguyen, and Linh Nguyen
Forthcoming Paper
“Credit supply shocks: financing real growth or takeovers?” by Tobias Berg, Daniel Streitz, and Michael Wedow
Forthcoming Paper
“Capital Structure and the Yield Curve” by Diogo Duarte, Ozde Oztekin, and Yuri F. Saporito
Paper Spotlight: Sharing R&D Risk in Healthcare via FDA Hedges
Recent estimates suggest that the cost of developing a single new drug in the biopharmaceutical sector is $2.6 billion, confirming the very large amounts of money that medical companies invest to develop a new treatment. Biomedical companies also face the risk of very low rates of success, not only due to the inherent scientific risk of developing… Read More »Paper Spotlight: Sharing R&D Risk in Healthcare via FDA Hedges
RCFS Award Winners at the Cavalcade
Photos from the SFS Cavalcade are now available on the conference website.